In adults with new onset type 2 diabetes, GLP‐1 receptor agonist and SGLT‐2 inhibitor utilization has markedly increased, coordinating with evolving guidelines that emphasize cardiovascular and chronic kidney disease management. This evidence concerns the gene SLC5A2 and chronic kidney disease.